Answers are grounded in this paper and cite their sources.
Background: BRAVE-AA-PEDS (NCT05723198) is a randomised, double-blind, phase 3 trial of baricitinib (BARI) for children and adolescents with severe alopecia areata (AA). We assessed maintenance of efficacy through Week (W)76 and safety up to 2.5 years in adolescents (age 12 to <18 years). Methods: Data were pooled by treatment arm from cohort 1 (randomised 1:1:1 to BARI 4mg, BARI 2mg, placebo) and cohort 2 (randomised 1:1 to BARI 4mg, BARI 2mg). Efficacy was assessed W52–W76 among patients meeting W52 response criteria and remaining on their same dose through W76. In the 4mg arm, this comprised patients with W52 Severity of Alopecia Tool (SALT) score <20. In the 2mg arm, SALT <10 AND clinician-reported outcome eyebrow AND eyelash scores [0,1]), termed “deep, multi-site response” (DMR), at W52 and W64. Safety is reported as incidence rates (IR) per 100 patient-years of exposure (PYE) in two datasets: All-BARI (N=415; any dose of BARI); Extended-BARI (continuously treated with 2mg [N=166] or 4mg [N=168]). Results: In the BARI 4mg arm, 57.1% (n=96/168) achieved SALT ≤20 response at W52; 92.7% of responders maintained SALT ≤20 at W76. Most 4mg responders had deep scalp responses (SALT ≤10, 79.2%; ≤5, 68.8%; 0, 44.8%) at W52; rates were relatively steady through W76. DMR was achieved by 42.9% (n=72) in the BARI 4mg arm at W52; of those achieving DMR, 95.8% maintained DMR at W76. In the BARI 2mg arm, 36.5% (n=61/167) achieved SALT <20 at W52; 25.1% (n=42) achieved DMR. 83.3% of 2mg DMR-responders maintained DMR at W76. The most common adverse events in All-BARI (615.8 PYE; median/maximum exposure, 80.6 and 131.4 weeks) were acne (IR, 11.2) and nasopharyngitis (IR, 9.9). IRs for serious adverse events were 3.6 for BARI 4mg and 1.0 for 2mg. There were no VTE/PEs, MACE, or deaths. Conclusions: BARI 4mg responders maintained SALT responses through W76 and >80% of BARI 2mg DMR-responders maintained DMR. Maintenance of DMR was >95% among BARI 4mg DMR-responders. No new safety signals were identified.
No takes yet. Share an insight, caveat, or question.
Craiglow et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: